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Are these the insulins of the future?
J.Markussen's group at Novo published two papers in the
previous issue of Protein Engineering on a novel combination
of protein engineering by genetic manipulation and chemical
semisynthesis. These papers demonstrate that the two methods
are, in the given system, much more powerful than either alone.
However, the thoroughness with which the authors document
both this conclusion, and their physico-chemical studies on their
new analogues, should not cause us to overlook another aspect,
namely that these two papers are the first public indication that
Novo may have taken a significant step towards a new genera-
tion of insulins. These insulins might permit a real improvement
in the control of mobilization from the injected subcutaneous
depot.
The analogue in which Thr827 is exchanged for an arginine
residue, and in which the C-terminus of the B-chain is amidated
has, as one would expect, a pi considerably higher than that of
the native hormone. What could not have been predicted is the
effect of these substitutions on the crystallization properties of
the product.
The ability of native insulin to form remarkably uniform
rombohedral crystals (~ 25 /tin along each edge) is well known
and has been the basis of many of Novo's long-acting prepara-
tions. If one injects a preparation containing a suspension of these
crystals as a subcutaneous depot, they take a considerable time
to dissolve. Thus, the crystalline insulin is mobilized more slowly
from the depot than would be the case for soluble, or amorphous,
insulin. It is obvious from the papers under discussion that Novo
are now at least considering dispensing the new insulin analogues
as a solution (mildly acidic, but unbuffered). The pH of the in-
jected depot would soon rise, due to the buffering power of the
tissue fluids, and during this phase there could be an initial period
of rapid mobilization of the soluble analogue. Soon, however,
a pH value would be reached at which the analogue will sudden-
ly crystallize, giving thereafter a much slower insulin release.
The tendency to crystallize seems to depend very sharply on zinc
content, and it would appear that different preparations could be
made having different kinetics of crystallization, and thus of
mobilization, depending on the amount of zinc present.
In what way does all of this constitute an advance with a real
prospect of benefits to patient care? It is obviously too early to
say, and Markussen's group are careful not to make any exag-
gerated claims. However, if all went well, even the simple fact
of being able to dispense insulin as a solution could in itself be
a considerable help to the patient, in that it would permit him
or her always to inject precisely the same dose. Current crystalline
suspensions need to be shaken to homogeneity before injection,
and tests show that this is surprisingly difficult to do, with
cumulative effects on the actual dose employed as a given bottle
is used up. Also, many of the newer forms of injection equip-
ment, much more acceptable to the patient, do not lend themselves
to shaking of any kind. (If the reader feels that mundane details
of this kind are out of place in a scientific research journal, he
or she is unlikely to be a diabetic. The rest of us might wish
to recall just how many of our fellow citizens are obliged to build
their lives around factors of this sort.)
The biphasic release mentioned above may well prove too dif-
ficult to control reliably. It might well prove necessary always
to work at concentrations of zinc that, while low, have already
more or less suppressed the rapid phase. However, this would
still leave an immensely useful range of conditions in which the
long-acting phase of mobilization could be subjected to fine tun-
ing with a facility and precision never before possible.
Even from the details given in these papers, it seems clear that
such analogues (as well as native human insulin) could be made
easily on an industrial scale by the new methods. Only one ma-
jor problem appears to remain before attempting to see by ex-
periment if this type of analogue could in practice realize its
promise for improved treatment. Will they be immunogenic? No
data are yet offered, and we must await events. However, the
most desirable of the substitutions look to be less likely to con-
fer immunogenicity on the analogue than do, for example, the
three natural substitutions that separate bovine from human in-
sulin. Bovine insulin has been one of the mainstays of insulin
therapy in Man for more than 50 years.
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Commission of the European Communities:
Biotechnology Action Programme (BAP)
Conference on 'Enzyme engineering: protein design and
applications in biocatafysis', Capri, Italy, May 2 — 6, 1987
It was in the Certosa San Giacomo gallery, with its medieval
quadrangle that, during five days in May, twentieth century Euro-
pean biotechnology assessed its progress against a backdrop of
seventeenth century Italian art. The BAP programme, as it is
now called, was established in 1985 as a successor to the pioneer-
ing Biomolecular Engineering Programme (BEP) (1982-1986)
which in the early 1980's coaxed the European scientific com-
munity in the direction of a centrally organised transnational
research programme. The success of this initiative is best
measured by reference to the 1987 BAP statistics: a total of 262
research contracts in the entire programme of which 73 related
to Enzyme Engineering were presented at the conference by then-
project leaders and numerous coworkers from all member states
of the community.
BAP represents the second phase of the initiative and has ob-
viously learned lessons from its predecessor. One of these lessons
is that is is not enough to support 'applied enzymology' without
simultaneously nurturing the supporting technologies. The pre-
sent programme comprises many of those subject areas present
in BEP, such as enzyme and protein engineering, genetic
engineering, cell culture technology and culture collection. In
addition, a subprogramme, 'contextual measures', was conven-
ed jointly, bringing to the discussion such diverse topics as data
capture techniques, data banks, computer models and advanced
software. The combination of these basic scientific disciplines
with the technological 'tools' will, it is hoped, place European
industry and agriculture in a position to more readily exploit the
discoveries of biotechnology into the 1990s.
The meeting began with an opening address by Alan Fersht.
On this occasion Fersht talked about his highly original work
on subtilisin in which subtle changes in the position and character
of charged groups at the periphery of an active site can lead to
dramatic effects on catalytic activities at different pHs. These
activity changes are due to through-water electrostatic effects on
the pKa of the active site histidine and in the most dramatic case
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